<p>Teva Canada Limited has announced a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for Mayzent® (siponimod), an oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the agreement, Teva Canada will take on exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada. The partnership aims to ensure continued access to Mayzent® for Canadian patients and healthcare professionals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via CNW (Ref. ID: C5864) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

TEVA

Teva Canada Signs Agreement with Novartis to Commercialize Mayzent for MS Patients